FDA Approves Medicine for Idiopathic Pulmonary Fibrosis
October 15th, 2014
On October 15, 2014, the FDA approved Esbriet®(pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).
News in brief
- Approximately 100,000 people in the United States have IPF, an irreversible and fatal lung disease
- Esbriet was approved under FDA’s Breakthrough Designation program
- Expected availability in the US within two weeks
Supporting Information
“This is a historic day for the people and their families in the United States who live with this deadly, incurable disease. With today’s approval of Esbriet in the United States, people with IPF finally have an FDA-approved medicine that may slow the worsening of the disease.”